PIOMBINO DESE, Italy / Mar 11, 2025 / Business Wire / Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Healthcare Forum taking place from Tuesday, March 18 to Wednesday, March 19, 2025.
The Company will present on Tuesday, March 18, at 3.00 p.m. (ET). A live webcast will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. A replay of the webcast will be available for approximately 90 days after the event.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value-added solutions to clients.
For more information, please visit: www.stevanatogroup.com.
Last Trade: | US$19.13 |
Daily Change: | 0.11 0.58 |
Daily Volume: | 535,342 |
Market Cap: | US$948.850M |
November 11, 2024 November 05, 2024 October 01, 2024 August 29, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load